Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #69 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Ind-Swift Laboratories Limited (this stock) | 3,381 | 55.4 | 3.0% | 299.3% | — | 60 | 36 | 52 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 191 | 33 | 25 | ₹ |
| March 31, 2026 | 170 | 12 | 15 | ₹ |
| Dec. 31, 2025 | 151 | 16 | 10 | ₹ |
| Sept. 30, 2025 | 153 | 10 | 8 | ₹ |
| June 30, 2025 | 153 | 10 | 9 | ₹ |
| March 31, 2025 | 138 | 230 | 222 | ₹ |
| Dec. 31, 2024 | 9 | -1 | 0 | ₹ |
| Sept. 30, 2024 | 12 | 1 | 0 | ₹ |
| June 30, 2024 | 33 | 1 | 1 | ₹ |
| March 31, 2024 | 393 | 373 | 239 | ₹ |
| Dec. 31, 2023 | 288 | 24 | 19 | ₹ |
| Sept. 30, 2023 | 290 | 39 | 32 | ₹ |
| June 30, 2023 | 310 | 32 | 17 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 641 | 49 | 41 |
| March 31, 2025 | 562 | 258 | 250 |
| March 31, 2024 | 1,281 | 582 | 421 |
| March 31, 2023 | 1,207 | 87 | 48 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | -63 | -73 | 142 | 88 | -151 |
| March 31, 2025 | -25 | -110 | 69 | 64 | -90 |
| March 31, 2024 | -181 | -104 | 699 | 45 | -225 |
| March 31, 2023 | 195 | -13 | -186 | 13 | 182 |
| March 31, 2022 | 150 | 5 | -141 | 18 | 132 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,673 | 1,384 | 1,297 | 6 | 12 | 977 | 255 | 430 | 275 | 148 |
| March 31, 2025 | 1,438 | 1,173 | 1,104 | 15 | 26 | 865 | 221 | 428 | 260 | 114 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
